Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H11NO3 |
Molecular Weight | 193.1992 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NC1=CC=C(CC(O)=O)C=C1
InChI
InChIKey=MROJXXOCABQVEF-UHFFFAOYSA-N
InChI=1S/C10H11NO3/c1-7(12)11-9-4-2-8(3-5-9)6-10(13)14/h2-5H,6H2,1H3,(H,11,12)(H,13,14)
Molecular Formula | C10H11NO3 |
Molecular Weight | 193.1992 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/9918236Curator's Comment: description was created based on several sources, including
http://www.clinexprheumatol.org/article.asp?a=1640
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9918236
Curator's Comment: description was created based on several sources, including
http://www.clinexprheumatol.org/article.asp?a=1640
Actarit (MS-932) is an anti-inflammatory drug developed in Japan for use in rheumatoid arthritis (RA). Actarit suppresses adjuvant arthritis through modulation of the immune system. Actarit acts on RA synovial cells to reduce cell-cell interactions with autologous synovium infiltrating lymphocytes and to inhibit proinflammatory cytokine and MMP production, leading to amelioration of symptoms of RA.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
[Effect of actarit combination therapy in patients with active rheumatoid arthritis resistant to gold agents]. | 2001 Jun |
|
Glucosides of Chaenomeles speciosa remit rat adjuvant arthritis by inhibiting synoviocyte activities. | 2003 Nov |
|
[A case of rheumatoid arthritis/Sjogren's syndrome with acute renal failure due to hyperuricemia associated with mizoribine therapy]. | 2004 Jun |
|
[Examination of the escape phenomenon in disease modifying antirheumatic drugs]. | 2005 Mar |
|
The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis. | 2006 |
|
Photosensitizing properties of Actarit, an antirheumatic drug. | 2008 |
|
Inhibitory effect of some acetyl esters and acetamides on glycation of the histone H1. | 2008 Jul-Aug |
|
Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. | 2008 Mar 20 |
|
A new low-field extremity magnetic resonance imaging and proposed compact MRI score: evaluation of anti-tumor necrosis factor biologics on rheumatoid arthritis. | 2009 |
|
Modeling the solubility of pharmaceuticals in pure solvents and solvent mixtures for drug process design. | 2009 Nov |
|
Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. | 2010 Jun 15 |
|
Determination of actarit from human plasma for bioequivalence studies. | 2010 Nov |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.clinexprheumatol.org/article.asp?a=1640
Curator's Comment: Actarit was administered at 300 mg/day and was used throughout the study period. The duration of treatment was 24 weeks. During this study there were no significant adverse reactions requiring the withdrawal of treatment.
300 mg/day, duration of treatment is 24 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9918236
rheumatoid arthritis primary synovial cells were co-cultured with actarit at 10(-4)-10(-7) M
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 17:51:13 UTC 2022
by
admin
on
Fri Dec 16 17:51:13 UTC 2022
|
Record UNII |
HW5B6351RZ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29634
Created by
admin on Fri Dec 16 17:51:13 UTC 2022 , Edited by admin on Fri Dec 16 17:51:13 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
170317
Created by
admin on Fri Dec 16 17:51:13 UTC 2022 , Edited by admin on Fri Dec 16 17:51:13 UTC 2022
|
PRIMARY | |||
|
2018
Created by
admin on Fri Dec 16 17:51:13 UTC 2022 , Edited by admin on Fri Dec 16 17:51:13 UTC 2022
|
PRIMARY | |||
|
DTXSID0020020
Created by
admin on Fri Dec 16 17:51:13 UTC 2022 , Edited by admin on Fri Dec 16 17:51:13 UTC 2022
|
PRIMARY | |||
|
242-511-3
Created by
admin on Fri Dec 16 17:51:13 UTC 2022 , Edited by admin on Fri Dec 16 17:51:13 UTC 2022
|
PRIMARY | |||
|
HW5B6351RZ
Created by
admin on Fri Dec 16 17:51:13 UTC 2022 , Edited by admin on Fri Dec 16 17:51:13 UTC 2022
|
PRIMARY | |||
|
CHEMBL1885632
Created by
admin on Fri Dec 16 17:51:13 UTC 2022 , Edited by admin on Fri Dec 16 17:51:13 UTC 2022
|
PRIMARY | |||
|
M1394
Created by
admin on Fri Dec 16 17:51:13 UTC 2022 , Edited by admin on Fri Dec 16 17:51:13 UTC 2022
|
PRIMARY | Merck Index | ||
|
ACTARIT
Created by
admin on Fri Dec 16 17:51:13 UTC 2022 , Edited by admin on Fri Dec 16 17:51:13 UTC 2022
|
PRIMARY | |||
|
SUB05255MIG
Created by
admin on Fri Dec 16 17:51:13 UTC 2022 , Edited by admin on Fri Dec 16 17:51:13 UTC 2022
|
PRIMARY | |||
|
18699-02-0
Created by
admin on Fri Dec 16 17:51:13 UTC 2022 , Edited by admin on Fri Dec 16 17:51:13 UTC 2022
|
PRIMARY | |||
|
6549
Created by
admin on Fri Dec 16 17:51:13 UTC 2022 , Edited by admin on Fri Dec 16 17:51:13 UTC 2022
|
PRIMARY | |||
|
84
Created by
admin on Fri Dec 16 17:51:13 UTC 2022 , Edited by admin on Fri Dec 16 17:51:13 UTC 2022
|
PRIMARY | |||
|
C73298
Created by
admin on Fri Dec 16 17:51:13 UTC 2022 , Edited by admin on Fri Dec 16 17:51:13 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |